Dermatologic and Ophthalmic Drugs Advisory Committee
Committee Meeting on June 17, 2011, from 8 a.m. to 4:30 p.m.
Agenda: On June 17, 2011, the committee will discuss biologics license application (BLA) 125387, aflibercept ophthalmic solution, proposed trade name EYLEA, sponsored by Regeneron Pharmaceuticals, Inc., indicated for the treatment of neovascular age-related macular degeneration (wet AMD)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment